ArticleBMC pulmonary medicine2025
Real-world clinical and economic outcomes associated with supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with fibrosing interstitial lung disease (ILD) experience a decline in lung function with progressive symptoms, poor response to treatment, and reduced quality of life. While supplemental oxygen therapy is commonly prescribed in clinical practice for patients with fibrosing ILD, the long-term outcomes associated with oxygen therapy remain unclear. This study aimed to address this knowledge gap.
methodsThis non-interventional study used the Optum
resultsA total of 24,680 patients who initiated oxygen therapy were successfully matched to those who did not. The mean age of the study cohort was 68.9 years and 50.9% were male. Mortality was significantly higher in the oxygen cohort vs. the no oxygen cohort (54.0% vs. 26.3%, p < 0.001). Similar trends were observed for hospitalizations and probable acute exacerbations. The oxygen cohort had significantly higher all-cause healthcare resource utilization (HCRU) across all categories and incurred greater total all-cause healthcare costs. Similar patterns were seen in fibrosing ILD-related HCRU and costs.
conclusionsInitiation of oxygen therapy in patients with fibrosing ILD is associated with significantly higher mortality, increased hospitalizations, and greater healthcare utilization and costs. However, these findings do not imply that oxygen therapy causes harm; rather, oxygen use likely reflects more advanced or rapidly progressing ILD. These results highlight the need for earlier and more effective interventions to delay disease progression and reduce the burden of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.